Prepared by Lyophilized Peptides Editorial Team · Updated October 24, 2026 · 9 min read
Direct answer
A useful lyophilized peptide powder specification names the exact commercial material, lists each required test, identifies the analytical procedure, and gives an acceptance criterion for every test. It also states the supplied format, packaging, storage, shelf-life basis, required batch documents and change-notification rules.
Last technical review: October 24, 2026. Prepared for cosmetic ingredient, filled-vial and private-label B2B projects.
Start with one unambiguous commercial identity
A specification should let purchasing, quality control and the supplier identify the same material without relying on a sales name. Record the peptide name, sequence or other identity reference where appropriate, chemical form, counterion or salt form, modification, grade, supplied format and composition basis. For a cosmetic project, add the proposed INCI name and intended use, then verify the destination-market position separately. The European Commission states that an INCI name in CosIng does not mean an ingredient is approved for cosmetic use. If the item is a formulated lyophilized cake, list the peptide and supporting excipients or refer to a controlled composition document. State whether the order covers bulk powder, a filled vial, an activator set or a finished kit. Product code, nominal fill and pack configuration belong in the same identity block so that the quotation, label, COA and shipment can be reconciled.
Identity fields to lock before sampling
- Controlled product name and supplier product code
- Sequence, INCI or another appropriate identity reference
- Salt, counterion, modification and composition basis
- Bulk powder, filled cake, activator set or finished-kit format
- Nominal fill, unit count and primary packaging configuration
- Cosmetic intended use and destination-market review status
Write every requirement as test, method and acceptance criterion
ICH Q6A defines a specification as a list of tests, references to analytical procedures and appropriate acceptance criteria. That definition comes from a pharmaceutical guideline, so it does not turn a cosmetic peptide project into a pharmaceutical submission. It does provide a sound drafting discipline. Each row should answer three questions: what is measured, how it is measured and what result is acceptable. “Purity: high” fails all three. A controlled row might name chromatographic purity, reference the current HPLC method and state a project-specific limit. The limit must come from development, batch history, safety, stability or an agreed commercial requirement. Avoid copying a competitor’s figure when the formulation, method or reporting basis differs. Units, calculation basis and result format should be explicit. If a test is informational during development but required for commercial release, mark that status and the point at which it changes.
Specification row anatomy
| Field | What to record |
|---|---|
| Test | The named quality attribute, such as identity, appearance or water content |
| Procedure | A controlled method number, compendial reference or agreed test description |
| Criterion | A numerical limit, range or clearly defined qualitative requirement |
| Stage | Development, in-process, release, stability or periodic testing |
| Report | Units, calculation basis, significant figures and COA presentation |
Select attributes that match the supplied peptide format
The test panel should follow the product that changes hands. Bulk peptide material may need identity, chromatographic purity, content or assay, appearance, water and other impurity controls selected for the molecule and manufacturing route. A formulated lyophilized vial adds fill, cake appearance, residual moisture, reconstitution behavior and container-closure checks. A powder-and-activator kit also needs activator specifications, component count, compatibility, labeling and directions. Microbiological controls depend on the material, process, packaging and intended cosmetic use; the specification should name the test and criterion when required. FDA’s cosmetic GMP checklist expects raw materials, in-process samples and finished products to be examined for identity and compliance with physical, chemical, microbial and unwanted-contaminant specifications. It does not prescribe one universal peptide panel. Choose attributes through a documented risk review, then explain why any commonly expected test is omitted, calculated or handled as an in-process control.
Format-specific buyer matrix
| Supply format | Attributes often considered |
|---|---|
| Bulk peptide material | Identity, purity profile, content basis, appearance, water and route-specific impurities |
| Filled lyophilized vial | Bulk controls plus fill, cake appearance, moisture, closure and reconstitution |
| Powder with activator | Both component specifications, ratio, compatibility, directions and in-use conditions |
| Private-label kit | Formula, components, artwork, unit count, assembly and shipping configuration |
Connect release criteria to packaging and shelf-life evidence
A batch can meet its release tests and still fail later if the specification ignores storage, closure and distribution. Record the approved vial, stopper, cap, secondary barrier and pack count, or link them to a controlled packaging specification. State storage conditions for the sealed dry product, the activator and the reconstituted system separately when their conditions differ. The shelf-life statement should identify the tested formula and container configuration. Stability work should follow the attributes most likely to change, which may include purity profile, assay or content, moisture, appearance, reconstitution and microbiological quality. ICH Q6A treats specifications as one part of a wider control strategy that also includes development, validated procedures, process controls and stability testing. Cosmetic projects can use that principle without borrowing pharmaceutical claims. When a packaging component, formula or manufacturing process changes, review the supporting stability rationale before carrying the same limits and shelf-life statement forward.
Packaging and stability fields
- Primary container, stopper, cap and secondary barrier
- Sealed-product, activator and in-use storage conditions
- Declared shelf life or retest period and its evidence basis
- Transport protection and excursion-review responsibility
- Stability tests, time points and acceptance criteria
- Triggers for compatibility or stability reassessment
Control the version that governs each commercial batch
Give the specification a document number, revision, effective date and approval record. The purchase order should identify the applicable revision or attach an agreed copy. The batch COA then reports results against that version; it should not introduce new tests, units or limits without explanation. Define who may approve a change and how far in advance the supplier must notify the buyer about changes to formula, raw-material source, manufacturing site, analytical method, packaging or labeled storage. Keep superseded versions so complaints and repeat orders can be traced to the requirements in force at the time. FDA’s cosmetic GMP checklist calls for records covering raw materials, manufacturing, laboratory results, finished-product control and distribution. ISO 22716 covers production, control, storage and shipment of cosmetic products. A specification works inside those records. It cannot replace batch documentation, a quality agreement or destination-market compliance review.
Document-control checklist
- Document number, revision, effective date and approvers
- Purchase-order reference to the governing specification
- COA fields mapped to release tests and criteria
- Deviation, out-of-specification and retest rules
- Change-notification categories and notice periods
- Retention of superseded versions and batch records
Use this buyer-ready specification structure
A practical document can stay concise if it separates fixed requirements from supporting references. Page one should identify the material, format, intended cosmetic use, manufacturer or supply route and governing revision. The main table should list tests, method references and acceptance criteria. Later sections can cover sampling, packaging, labeling, storage, shelf life, batch documents, change control and approval signatures. Put explanatory development notes in a justification file instead of crowding the release table. That separation helps a laboratory report the correct result and lets a buyer compare suppliers without losing the method context. Before approval, conduct a line-by-line reconciliation against the quotation, sample label, TDS, SDS, proposed COA and packaging bill of materials. Any conflict should be resolved in writing. The signed specification should describe the product the supplier will manufacture and release. Website descriptions and generic templates cannot serve as the controlling batch document.
Recommended section order
- Document control and commercial identity
- Composition, grade, intended use and supplied format
- Tests, procedures, criteria and reporting units
- Sampling, packaging, labeling and storage
- Shelf-life basis and stability commitments
- COA, supporting documents, changes and approvals
Frequently asked questions
Buyers often receive a specification after the quotation, when product identity and test language have already drifted across several documents. The answers below address the decisions that should be settled before sample approval. They avoid universal purity, moisture, microbial or shelf-life numbers because those limits depend on the exact peptide, formulation, method, process, packaging and intended use. A supplier should explain the evidence behind each criterion and identify which document controls when a TDS, quotation or previous COA uses different wording. The final specification should also state whether a result is batch-specific, typical, calculated or tested periodically. That distinction prevents a typical marketing value from being treated as a release result. Qualified technical and regulatory reviewers should assess the document for the actual destination market.
Is a COA the same as a product specification?
No. The specification states the agreed tests, methods and acceptance criteria. The COA reports the applicable results for a named batch and indicates whether that batch met the governing requirements.
Should every website parameter appear in the specification?
Only parameters that define or control the supplied material belong in the specification. General descriptions and typical values need a clear status and should not become release criteria by accident.
Can one specification cover bulk powder and filled vials?
A shared bulk-material section may be possible, but the filled vial adds formula, fill, lyophilized-cake, closure, packaging and reconstitution requirements. Keep the commercial formats clearly separated.
Who should approve the final specification?
The supplier’s authorized quality or technical representative and the buyer’s responsible quality, technical or regulatory reviewer should approve it according to the organizations’ document-control procedures.
Related project resources
A specification draws information from several parts of a peptide project. The HPLC and LC-MS guide explains how method context changes the meaning of a purity or identity result. The residual-moisture article covers dry-cake attributes that may enter a filled-vial specification. The packaging guide addresses the vial, stopper and secondary pack referenced by the document. The COA article separates batch results from technical and safety information, while the supplier audit guide explains how buyers verify that the stated controls operate in practice. Reading these pages as one cluster gives procurement teams a consistent vocabulary for the RFQ, sample review, quality agreement and repeat order.
Authoritative sources and scope
ICH Q6A supplies the test, procedure and acceptance-criterion definition used as a drafting framework in this article. Its formal scope is new chemical drug substances and drug products, so the article does not present it as a cosmetic approval requirement. FDA’s cosmetic GMP checklist supports the sections on identity, specifications, testing and batch records. ISO 22716 provides the international cosmetics GMP context for production, control, storage and shipment and was confirmed as current in 2022. The European Commission CosIng page supports the caution around INCI names and regulatory status. These sources establish general principles. The exact specification still depends on the supplied product, supporting data, contract and destination-market assessment.